عنوان

Prescribing trends for biologic drugs among Ohio dermatologists

Number

LA2cg5r12t

.Language of Text, Soundtrack etc

انگلیسی

Title Proper

Prescribing trends for biologic drugs among Ohio dermatologists

General Material Designation

[Article]

First Statement of Responsibility

Iacullo, Julie; Kunzler, Elaine; Ezaldein, Harib H; Scott, Jeffrey F

Text of Note

The role of biologic therapies in the field of dermatology continues to evolve as newer drugs and biosimilars are introduced to the U.S. market. Prescribing patterns and expenditures regarding biologic drugs are not well described. To address this knowledge gap, a retrospective review was conducted using the Medicare Provider Utilization and Payment Data: Part D Prescriber dataset between January 1st, 2013 and December 31st, 2015. The primary outcome was claims per provider per calendar year. Secondary outcomes included drug cost, shared cost per dermatologist, and practice location. Median claims per provider remained stable between 2013 and 2014 (24 versus 23, respectively; P=0.64). The majority of 2015 claims were for adalimumab (50.1%) and etanercept (41.4%). Total spending from Medicare payment data for biologic drugs prescribed by Ohio dermatologists increased by

Date of Publication

2018

Title

Dermatology Online Journal

Volume Number

24/7

Entry Element

Iacullo, Julie; Kunzler, Elaine; Ezaldein, Harib H; Scott, Jeffrey F

Electronic name

[Article]

275578

a

Y